Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know

Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know

 

Oppenheimer has decided to maintain its Outperform rating of Ascendis Pharma ASND and lower its price target from $154.00 to $144.00.

Shares of Ascendis Pharma are trading up 8.7% over the last 24 hours, at $103.42 per share.

A move to $144.00 would account for a 39.24% increase from the current share price.

About Ascendis Pharma

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: BZI-AAR-UPDATEAnalyst Ratings